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Abstract
Background: The South African (SA) health system has employed an Essential Medicines List (EML) with Standard
Treatment Guidelines (STGs) since 1996. To date no studies have reported the changes in SA STG/EMLs. This study
describes these changes over time (1996–2013) and compares latest SA STG/EMLs with the latest World Health
Organization (WHO) Model EMLs to assess alignment of these lists.
Methods: A quantitative evaluation of SA STGs/EMLs at 2 levels of healthcare was performed to assess changes in
the number and ratio of molecules, dosage forms, and additions and deletions of medicines. The most recent WHO
EMLs (18th list, 4th list for children) and 2012 priority life-saving medicines for women and children (PMWC) list
were compared to the most recent available SA STG/EMLs (Primary Health Care (PHC 2008), Adult Hospital 2012,
and Paediatric Hospital 2013) at the time of the research.
Results: The number of molecules over the years increased for PHC STG/EMLs but decreased slightly for Adult and
Paediatric hospital STG/EMLs. The most additions and deletions over time occurred in the Adult hospital level STG/
EML (27 in 2006 and 44 in 2012). A comparison between the most recent SA STG/EMLs and WHO Model EML (18th
list) showed that a total of 112 medicines were absent on all SA STG/EMLs. A comparison of medicines for children
between the 2013 SA Paediatric Hospital level STG/EML and PMWC indicated that these lists were somewhat
aligned for most conditions as only 3 of 14 medicines and 11 of 20 vaccines were absent from SA STG/EMLs.
Conclusion: This is the first study in SA to investigate changes in National EMLs over time in relation to molecules,
dosage forms and therapeutic classes. It is also the first to compare the latest SA STG/EMLs to the WHO Model lists.
The results therefore provide insight into the trends and SA STG/EML processes over time.
Keywords: Essential medicines, Essential medicines lists, Priority medicines, Standard treatment guidelines, Health
systems research
Background
The essential medicines concept is recognized worldwide
as a tool to improve health equity and to promote the
cost-effective use of health resources. It is vital in coun-
tries with limited resources to not only manage health
services but also to provide guidance on the best way to
maximize available resources. It has been established
that the judicious selection of a limited number of
essential medicines results in improved medicine
management and enhanced quality of care. The Essential
Medicines List (EML) is a fundamental tool which
guides countries in the procurement and distribution
processes, and which ultimately reduces costs to both
the health care system and the patient [1, 2].
In 1977, the World Health Organization (WHO) de-
veloped a Model EML which is updated every 2 years. It
is a tool to guide countries to develop their own Na-
tional EML (NEML) [3].
The WHO defines essential medicines as
“those that satisfy the priority health care needs of the
population. These are selected with regard to public
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health relevance, evidence on efficacy and safety,
and comparative cost-effectiveness; and should be
available and affordable at all times within functioning
health systems. Countries then determine which
medicines are considered essential” [4].
In April 2011, WHO published a list of Priority Medi-
cines for Mothers and Children, which was revised in
2012 to Priority life-saving medicines for women and
children (PMWC). It is a subset of medicines from the
WHO EML developed by experts in the field of mater-
nal and child health. These medicines were selected tak-
ing into account the worldwide disease burden and
evidence of safety and efficacy. Priority conditions iden-
tified by WHO include: HIV/AIDS, malaria, pneumonia,
tuberculosis and diarrhoea for children, and for mothers:
post-partum haemorrhage; pre-eclampsia, sepsis, sexu-
ally transmitted infections and preterm birth [5].
South Africa (SA) has implemented an EML with
Standard Treatment Guidelines (STG) since 1996. This
was a key objective of the 1996 National Drug Policy for
South Africa (NDP) to ensure equity in health care for
all citizens after the fragmentation that was created
under apartheid [6].
Although the under-5 years mortality rate in South
Africa has decreased in recent years, from 60 deaths per
every 1 000 live births in 1990 to 41 in 2015, it still failed
to meet the target (20) set out in the Millennium Devel-
opment Goals (MDG) [7]. Ensuring access to simple and
affordable medicines, such as oral rehydration for diar-
rhoea could prevent death in children [8]. These medi-
cines including PMWC could be included in the SA
STG/EMLs and will contribute to achieving the new
proposed Sustainable Development Goals (SDGs) target
for child mortality by 2030. The target is to end prevent-
able deaths of new-borns and children under five years
and for countries to decrease neonatal mortality to 12
deaths per 1000 live births and children under-5 years
mortality to 25 deaths per 1000 live births [7].
This PMWC list was selected as it reflects WHO’s rec-
ommendation for the most important medicines for
mothers and children and according to Hill et al., (2012)
should be part of NEMLs. NEMLs are key policy tools
for promoting the supply of priority medicines, espe-
cially in the public sector [9]. The regular production,
updating and maintenance of NEMLs, that is evidence
based and transparent, is vital for the successful imple-
mentation of a national Essential Medicines Programme
(EMP) [10, 11]. SA still has a two-tiered healthcare sys-
tem encompassing both public and private sectors. The
public sector has three levels of care (primary health
care (PHC), Hospital level secondary and tertiary/quater-
nary level. There are 3 STG/EML publications, for PHC,
adult hospital and paediatric hospital care. The listing of
medicines for tertiary/quaternary care is quite different;
less detailed, and does not include STGs. The Tertiary
and Quaternary Level EMLs were published in November
2012 [12] but are not included in this study as it is a list of
recommendations for use of medicines for certain
indications.
The PHC EML has been revised four times (editions
in 1996; 1998; 2003; 2008; 2014); the Adult Hospital
level revised three times (1998; 2006; 2012; 2015) and
Paediatric hospital level revised twice (1998; 2006; 2013).
WHO recommends regular revision of lists to ensure
the selection of medicines remains credible, current, and
relevant to the healthcare needs of the population and
the country’s budget for health care [11]. However, these
lists should not be reviewed too quickly as implementa-
tion and acceptance is slow within health systems due to
challenges of alignment of procurement processes with
the list [13]. The National Essential Medicines List
Committee (NEMLC) is responsible for compiling and
revising STGs and/or EMLs for each level.
The SA EMLs are derived from the national STGs.
The STGs are presented in chapters which are organized
according to the organ systems of the body with compo-
nent topics in alphabetical order. Each guideline outlines
the non-pharmacological management followed by the
recommended medicines and dosages per disease condi-
tion. Medicines are listed as their generic name or Inter-
national Non-proprietary Name (INN). As the process
of medicine selection has evolved, more recent editions
of the STGs include the designation of therapeutic clas-
ses under the “Medicine treatment” section which lists
an example of a medicine within that therapeutic class.
Therapeutic classes were designated in cases where none
of the members within that class exhibits significant
benefit over another. The intention of limiting the listing
to therapeutic classes was to promote competition for
procurement of medicines to obtain the best possible
price during the tender process. The provincial Phar-
macy and Therapeutics Committees (PTC) then decides
on their medicine of choice within a therapeutic class,
based on this tender process, and lists this on their local
procurement catalogue [14, 15].
This is similar to the square box symbol used in the
WHO Model list of Essential medicines. The square box
symbol indicates that the medicine listed is an example
of a clinically equivalent medicine from the same
pharmacological class. This allows flexibility during the
medicine selection process as countries can then select
medicines from a class dependent upon current cost and
availability [11]. Currently, there is no published infor-
mation on the changes, process and evaluation of the SA
STG/EMLs. This study therefore aims to provide insight
into the development of the SA STG/EMLs over time
(1996–2013) and to provide a comparative analysis with
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the latest WHO Model EMLs and PMWC list to assess
alignment of these lists.
Methods
An observational, descriptive study design was employed
to quantitatively analyse SA STG/EMLs over time. Hard
copies of SA STG/EMLs (1996–2013) were converted
into Microsoft EXCEL workbooks for ease of compari-
sons across years and editions.
SA STG/EMLs were assessed in terms of quantitative
changes. The number and ratio of molecules, dosage
forms, additions and deletions of medicines per revision
were calculated.
The STG/EMLs used in this study were: PHC (1996,
1998, 2003, 2008); Adult hospital level (1998, 2006,
2012) and Paediatric hospital level (1998, 2006, 2013).
The SA STG/EML procurement catalogue,1 which is a
list of tendered medicines as per EML recommendation
at that time, was used to complete missing information
on dosage forms of a molecule in the NEML [16].
The most recent WHO EMLs (18th list [17]; 4th list
for children [18]) and 2012 WHO PMWC list were used
to compare the most recent SA STG/EMLs for each
level (PHC 2008; Adult Hospital 2012; Paediatric Hos-
pital 2013) for alignment of lists. At the time of this ana-
lysis, these were the latest versions of SA STG/EMLs.
Both the core [17] and complimentary [17] lists of the
WHO Model lists were included in the analysis. Medi-
cines (single molecules or combinations) that did not ap-
pear on any of the SA STG/EMLs but were present on
the latest WHO Model EMLs were considered absent
and recorded in a table. These results reflect the lists for
PHC and Hospital levels (Adult and Paediatric).
The term “molecule” refers to the generic name or INN
of a medicine and not the different dosage forms listed.
Duplicates are considered as molecules that are listed
more than once in the same STG/EML or in different
sections of the list. The list of molecules for each STG/
EML was analysed in EXCEL using a what-if analysis to
flag and identify a molecule that appeared more than
once in the same list. Such molecules were assigned a
value of 1 which was then totalled to provide the total
number of duplicate molecules for that list. This number
of duplicates was then subtracted from the total number
of molecules for the list to provide the number of
unique molecules i.e. the number of molecules per list
excluding duplicates. Whilst calculating the total num-
ber of duplicates allows for comparison with other re-
ports it is also a reflection of the different ways the lists
are arranged. The WHO Model EMLs are arranged ac-
cording to pharmacological class whilst the SA STG/
EMLs are arranged according to organ systems.
Over the years the SA STG/EMLs have been devel-
oped to include the listing of therapeutic classes with an
example of a medicine within this class as opposed to
listing a single preferred molecule as the medicine of
choice for a specific indication. Therefore, for this study
the number of therapeutic classes listed in each STG/
EML was counted and compared across STG/EMLs and
across years.
The WHO square box notation to illustrate the listed
medicines with therapeutic class alternatives was accom-
modated for in the comparative analysis of STG/EMLs.
When such a box appeared on the WHO EML, the SA
STG/EML listing of a molecule in the same class was
considered and if present was considered as concord-
ance between the lists. If no therapeutic alternative was
listed, the molecule was considered to be absent on the
SA STG/EML and subsequently recorded in the table.
The comparison was performed for both core and
complimentary lists of medicines as listed by WHO.
A year-on-year comparison of molecules was made by
comparing the older edition STG/EML with the subse-
quent issue. This was done for both PHC and Hospital
levels. A new appearance of a molecule in the later ver-
sion STG/EML was considered an addition to the list
whilst the omission of a molecule from a later version
was considered a deletion.
Ratios of dosage forms per molecule per STG/EML
are calculated as: The total number of dosage forms di-
vided by the total number of molecules. The ratios of
molecules per organ system classification between the
first and latest STG/EMLs are calculated as: The total
number of molecules (latest STG/EML) divided by the
total number of molecules (First STG/EML). For the ra-
tio calculations a value <1 indicates a decrease and a
value >1 indicates an increase.
Results
Quantitative changes in the SA STG/EMLs over time
The first PHC STG/EML (1996) contained 180 mole-
cules including duplicates (134 molecules excluding
duplicates). The most recent PHC STG/EML (2008)
contained 231 molecules including duplicates (161 mol-
ecules excluding duplicates), showing an increase in the
total number of molecules over the years. Table 1 sum-
marizes these quantitative changes over time for all
STG/EMLs.
Both Adult and Paediatric hospital STG/EMLs had a
slight decrease in number of molecules excluding dupli-
cates from the first lists (1998) to the most recent lists
(2012 and 2013 respectively) as a result of using thera-
peutic classes as an option rather than individual thera-
peutic molecules for indications. For example, the 1998
Adult list did not contain any therapeutic classes whilst
the 2006 and 2012 editions contained 32 and 31 thera-
peutic classes respectively. The ratio of dosage forms per
molecule including duplicates per STG/EML edition
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decreased over time indicating fewer dosage forms per
molecule were listed due to therapeutic classes being
nominated.
SA STG/EMLs are arranged in 14 sections classified
according to organ systems of the body. Table 2 shows
that some sections expanded considerably over time
when compared to the others. At PHC level such sec-
tions include Blood and Blood-forming products (ratio
2.8); Cardiovascular system (ratio 1.8); Alimentary tract
and metabolism (ratio 1.5); Respiratory system (ratio
1.5); general anti-infectives for systemic use (ratio 1.4)
and central nervous system (ratio 1.4). At Adult hospital
level the ratio increased for the following sections: Sen-
sory organs (ratio 2.0); Blood and blood-forming prod-
ucts (ratio 1.3); respiratory system (ratio 1.3) and
cardiovascular system (ratio 1.2). At Paediatric hospital
level the Dermatologicals section tripled over time (ratio
3.3) whilst the following sections had a ratio of 1.6:
Genitourinary system and sex hormones; General anti-
infectives for systemic use; and Respiratory system. A
substantial decrease in ratios for antineoplastic and
immunomodulating agents at hospital level for both the
adult (ratio 0.3) and paediatric (ratio 0.2) was noted.
Table 3 summarizes the additions and deletions of
medicines per year of revision. The greatest changes
over time occurred in the Adult hospital level STG/EML
with net changes of 27 and 44 in 2006 and 2012 respect-
ively. Changes in 2006 were due to (i) additions of medi-
cines in the following sections: General anti-infectives
for systemic use (28 of which 10 were antiretroviral
medicines); central nervous system (17); Dermatologicals
(16); Blood and Blood-forming products (14) and the
cardiovascular system (14) and (ii) deletion of medicines
from the following sections: General anti-infectives for

















Primary Health Care 1996 134 180 201 1.12 0
1998 125 177 198 1.12 0
2003 140 202 219 1.08 6
2008 161 231 243 1.05 12
Adult Hospital 1998 364 397 447 1.13 0
2006 390 428 432 1.01 32
2012 357 395 407 1.03 31
Paediatric Hospital 1998 231 316 368 1.16 1
2006 240 348 384 1.10 12
2013 228 342 372 1.09 22
Table 2 Comparison of number of molecules per organ system classification between the first and latest SA STG/EMLs
Section of SA STG/EML Primary Health Care Adult Hospital Paediatric Hospital
1996 2008 Ratio 1998 2012 Ratio 1998 2013 Ratio
Alimentary Tract and Metabolism 25 37 1.5 52 49 0.9 50 44 0.9
Blood and Blood-forming Products 4 11 2.8 18 23 1.3 26 33 1.3
Cardiovascular System 12 22 1.8 34 41 1.2 33 26 0.8
Dermatologicals 21 17 0.8 21 17 0.8 7 23 3.3
Genitourinary System and Sex Hormones 18 17 0.9 30 28 0.9 5 8 1.6
Systemic Hormonal Preparations, excluding Sex Hormones 2 2 1.0 15 17 1.1 9 12 1.3
General Anti-infectives for Systemic Use 39 55 1.4 73 83 1.1 62 98 1.6
Antineoplastic and Immunomodulating Agents 0 0 0.0 29 8 0.3 30 5 0.2
Musculoskeletal System 4 4 1.0 11 12 1.1 8 3 0.4
Central Nervous System 21 30 1.4 58 53 0.9 41 41 1.0
Antiparasitic Products 10 10 1.0 9 7 0.8 10 9 0.9
Respiratory System 10 15 1.5 11 14 1.3 11 18 1.6
Sensory Organs 8 9 1.1 14 28 2.0 10 12 1.2
Various 6 2 0.3 22 15 0.7 14 10 0.7
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systemic use (19 of which 12 were antibacterials); Anti-
neoplastic and immunomodulating agents (14); Genito-
urinary System and Sex Hormones (12); Alimentary
Tract and Metabolism (13). Additions in the 2012 Adult
STG/EML occurred in the following sections: Sensory
Organs (12) and General anti-infectives for systemic use
(7) and for deletions: Alimentary tract and metabolism
(21); Dermatologicals (13); General anti-infectives for
systemic use (11); and Antineoplastic and immunomo-
dulating agents (11).
For the 2008 PHC STG/EML, the net change of 26
was attributed to additions in the General anti-infectives
for systemic use section (21 of which 15 were antiretro-
virals) and deletions in the following sections: Alimen-
tary tract and metabolism (8); Antiparasitic Products (7);
and Dermatologicals (5). The decentralization of services
to PHC, including the provision of antiretroviral therapy
[19–21], could be a reason for the addition of 15 antire-
trovirals in 2008, which extended anti-retroviral (ARV)
management to PHC facilities.
The largest change at the Paediatric hospital level (23)
was noted in 2006. Most additions (26) were noted in
the General anti-infectives for systemic use section (anti-
bacterials (8); antiretrovirals (6); antimycobacterials (6);
vaccines and immunoglobulins (5)); and Alimentary
tract and metabolism (21) and most deletions were
noted in the following sections: Alimentary tract and
metabolism (21); Dermatologicals (13); General anti-
infectives for systemic use section (11); central nervous
system (11); and Antineoplastic and Immunomodulating
agents (10).
Comparative analysis of SA STG/EMLs with WHO
model lists
A direct comparison of EMLs for WHO and SA posed a
challenge as the lists are arranged differently. The WHO
list reflects all levels of care and is not separated accord-
ing to levels as with SA STG/EMLs and on the basis of
services offered and the competency of the staff at each
facility [15].
The comparative analysis of the lists (Table 4: WHO
Model EML (18th list) compared with the latest SA
STG/EMLs (PHC 2008, Adult hospital 2006, Paediatric
hospital 2012) shows the medicines (individual mole-
cules and combinations) present on the WHO Model
EML (core and complimentary lists) but absent on all
latest SA STG/EMLs. The following sections showed the
most number of absent medicines: anti-infective medi-
cines (50); Antineoplastics and Immunosuppressives
(20); Immunologicals (11). A total of 112 medicines (79
core and 33 complimentary) were totally omitted from
all SA STG/EMLs combined. These differences may be
attributed to listing of medicines recommended globally
for conditions that may not be applicable in the SA setting
(such as the tropical diseases which are not addressed in
the SA STG/EMLs for which examples include leishman-
iasis and trypanosomiasis) or merely by virtue of medi-
cines not being registered or readily available in SA either
as individual molecules or as the listed combinations as is
the case with many of the antimalarials (examples include:
Amodiaquine; Proguanil; Artesunate; Artesunate + Amo-
diaquine; Artesunate +Mefloquine).
The comparison of medicines for children between the
SA STG/EMLs (2008 PHC and 2013 SA Paediatric Hos-
pital STG/EML) and 2012 WHO Model List of PMWC
(Table 5) showed some alignment for most conditions as
only 3 medicines (of which 2 were antimalarials not
available in SA) and 11 of the 20 vaccines were absent.
When compared for medicines for women, the SA
STG/EMLs (PHC 2008 and Adult 2012) and WHO list
of PMWC seem adequately aligned as only 5 medicines
did not appear on either level of SA STG/EML. These
included Azithromycin for STIs; Artesunate and Arte-
mether (which are not available in SA) for Maternal
Malaria; and 2 medicines for Contraception (injectable
oestradiol cypionate +medroxyprogesterone acetate and
implantable levonorgestrel-releasing implant.). However,
at least one medicine was listed on SA STG/EMLs for
each of these categories.
Discussion
Since inception in 1996, the SA STG/EMLs have
undergone substantial transformation in the number of
medicines (both molecules and dosage forms) made
available with subsequent editions impacting on
strengthening the provision for health care in the coun-
try. Subsequent to this research a 2014 version of the
PHC STG/EML and a 2015 version of the Adult
hospital STG/EML have been published by the SA Na-
tional Department of Health.
Main findings
There have been many additions and deletions of medi-
cines to the STG/EMLs over time. Possible reasons for
Table 3 Summary table of additions and deletions for each










Primary Health Care 1998 46 47 −1
2003 37 26 11
2008 60 34 26
Adult Hospital 2006 150 123 27
2012 47 91 44
Paediatric Hospital 2006 127 104 23
2013 93 96 −3
*Comparisons are year-on-year made with the previous edition of the STG/EML
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Table 4 Medicines appearing on the WHO Model EMLs but not on the SA STG/EMLs
Section Name of medicine (core list) Name of medicine (complementary list)
2. Medicine for pain and palliative care Docusate sodium









6. Anti-infective medicines Levamisole (not registered in SA),
Niclosamide,
Pyrantel,
Diethylcarbamazine (not readily available in SA,
can be obtained from pharma company),
Ivermectin (not registered in SA, can be obtained
after MCC approval)
Triclabendazole (not available for human use in SA)
Azithromycin,
Trimethoprim (available in combination with
Sulfamethoxazole),
Spectinomycin (not available in SA),
Clofazimine (available on named patient basis)
Ethambutol + Isoniazid
Ethambutol + Isoniazid + Rifampicin
Rifabutin







Lamivudine + nevirapine + stavudine (FDC)
Lamivudine + nevirapine + zidovudine (FDC)
Lamivudine + zidovudine (FDC)
Emtricitabine + Tenofovir (FDC)
Efavirenz + Emtricitabine + Tenofovir (FDC)
Oseltamivir
Ribavirin,
Diloxinide (not available in SA)
Miltefosine,
Paromomycin (not available in SA)
Sodium stibogluconate,
Amodiaquine (not available in SA)
Artemether (available in combination with lumefantrine)
Artesunate (not registered in SA, can be obtained through
the IV artesunate access programme on a named patient
basis after MCC approval)
Artesunate + amodiaquine (not available in SA)
Artesunate +mefloquine (not available in SA),
Mefloquine (not registered for treatment in SA)
Proguanil (not registered for treatment only prophylaxis
and in combination with Atovaquone)
Sulfadoxine + Pyrimethamine (no longer recommended
due to increased resistance)
Pyrimethamine
Sulfadiazine (available as silver sulfadiazine)
Pentamidine (not available in SA, available on named
patient basis)
Suramin sodium (not readily available in SA, can be
obtained on named patient basis)
Eflornithine (not readily available in SA, can be obtained
on named patient basis)
Melarsoprol (not readily available in SA, can be obtained
on named patient basis)
Nifurtimox (not available in SA)
Capreomycin,
Oxaminiquine (not available in SA)
Cycloserine (alternative terizidone is listed)
p-aminosalicylic acid (PAS),
potassium iodide
Pegylated interferon alpha (2a or 2b)
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deletions include safety and efficacy reasons; adverse ef-
fects and/or the availability of safer or cheaper alterna-
tives. For example, the NEMLC secretariat recently
issued a notice, to award a tender to a single member in
the macrolide class due to cost and clinical advantages
(dosing of 24 hourly compared to 6 hourly; improved
gastro-intestinal tolerability and consequently improved
patient compliance) [22].
Furthermore, the decrease in ratios of molecules be-
tween the first and latest STG/EMLs for the section on
antineoplastic and immunomodulating agents for both
the adult and paediatric hospital level lists may be attrib-
uted to the further differentiation of the health care sys-
tem into levels with the development of a tertiary/
quaternary medicine list in 2012, as many of these medi-
cines now appear on this latter list.
Over the years STG/EML changes have increased
provision at hospital level for mental health conditions,
neonatal conditions, palliative care, HIV/AIDS and re-
lated opportunistic infections. Large net changes result-
ing from the numerous additions and deletions of
medicines to each edition of STG/EML were noted for
most STG/EMLs that were revised after a period of
5 years (Table 3). During this time lapse there could
have been significant changes in the availability of more
generics per molecule thus reducing the cost of medi-
cines due to competition in the market. Furthermore,
the critical appraisal of evidence could have become
Table 4 Medicines appearing on the WHO Model EMLs but not on the SA STG/EMLs (Continued)
8. Antineoplastic and
immunosuppresives
Cytotoxics: Ciclosporin, asparaginase, calcium
folinate, carboplatin, chlorambucil, mercaptopurine,
cytarabine, dactinomycin, daunorubicin, dacarbazine,
doxorubicin, docetaxel, mercaptopurine, mesna,
thioguanine, etoposide, fluorouracil, ifosfamide,
paclitaxel, procarbazine, vinblastine,
10. Medicines affecting the blood protamine sulfate
12. Cardiovascular medicines Sodium nitroprusside






14. Diagnostic agents Amidotrizoate Meglumine iotroxate
15. Disinfectants and antiseptics Glutaral
16. Diuretics Amiloride
18. Hormones, other endocrine
medicines and contraceptives




Propylthiouracil (not available in SA)











21. Ophthalmological preparations Azithromycin
Latanoprost
Bevacizumab
23. Peritoneal dialysis solution Intraperitoneal dialysis solution




27. Vitamins and minerals Ascorbic acid (only available in a multivitamin
preparation)
Riboflavin (only available in a multivitamin preparation)
Sodium fluoride
Note: The tertiary/quaternary EML was not considered in this analysis
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more stringent over the years, contributing to numerous
additions and deletions in STG/EMLs.
The comparative analysis of the SA STG/EMLs and
the WHO PMWC shows that SA STG/EMLs are defi-
cient in the listing of vaccines as 11 out of the 20 vac-
cines listed on the PMWC list were absent on SA STG/
EMLs. In SA the immunization schedule is as per the
Expanded Programme on Immunization (EPI-SA), which
is outlined in the Vaccinator’s Manual published by the
SA National Department of Health [23], which does in-
clude the Rotavirus vaccine which is not listed in the SA
STG/EMLs (PHC 2008 and Paediatric 2013), though
reference to the EPI-SA is made in the STG/EMLs.
Vaccines such as Rubella and Mumps as part of the
Measles/Mumps/Rubella (MMR) vaccine, HPV, Menin-
gococcal and Hepatitis A are present on the PMWC list
but not listed on the EPI-SA and are only available in
the private sector of healthcare. These vaccines, for ex-
ample Rubella, Hepatitis A, and Mumps, with the excep-
tion of vaccines for tropical diseases, should be made
available in the public sector of healthcare, at the PHC
level at the least since this is the first point of contact
for most patients in SA. Of the twenty vaccines listed on
the PMWC, five are not applicable in SA and are not
listed on the EPI-SA (viz. Japanese encephalitis; yellow
fever; tick borne encephalitis; cholera and typhoid), and
5 are available in the private sector of healthcare only,
which can be considered at a later stage and self-
financed. SA did not meet the 2015 MDG target of 20
deaths per 100 000 live births for children under 5 years
[7]. Although the comparative analysis in our study
shows SA STG/EMLs and the WHO PMWC lists for
children are almost aligned for most conditions, this fur-
ther reiterates the importance for SA to adequately inte-
grate the country’s STG/EMLs with other clusters within
SA National Department of Health, especially with re-
gard to vaccines, which could be expanded, at PHC level
as these are considered priority life-saving medicines.
Further studies are required to analyse the discrepancies
between these lists to better describe the impact of the
differences on improving the under-5 mortality.
The previous increase in the under-5 child morbidity
could also be linked to other barriers to access to health-
care. A study conducted by Lalloo et al. (2004) reported
that although policies aimed at improving healthcare and
reducing inequities in access to health care were imple-
mented, these inequities still existed and over one quarter
of SA citizens were unable to access health care [24].
Differences between SA STG/EMLs and WHO Model
EMLs are expected since the WHO Model EML is merely
a guideline for the development of EMLs globally. Possible
reasons for discrepancies may include a medicine or vac-
cine not being considered essential to the burden of dis-
ease for SA; or differences in recommended therapy
between national and WHO guidelines; or certain medi-
cines listed on the WHO EML may not be licenced for
use in SA [25]. The arrangement of the WHO Model
EMLs according to pharmacological class is different to
that of the SA STG/EMLs which is arranged according to
organ systems. These may also be possible reasons for dif-
ferences between SA and studies in other countries.
Comparison with other studies
Similar studies to assess changes in countries’ EMLs and
compare alignment of lists with WHO EML have been
conducted in other countries [26–29]. This is the first
analysis to report changes in SA STG/EMLs in terms of
molecules, dosage forms and therapeutic classes. The
paucity of reports on STG/EML changes, together with
supporting documents detailing reasons for changes, by
the NEMLC hinders an in-depth analysis. This is in dir-
ect contrast to the more transparent reporting process
followed by the WHO, whereby all information pertain-
ing to the rationale and cited evidence for each change
(addition or deletion) is captured and subsequently pub-
lished as a Technical Report Series document. In previ-
ous years the SA STG/EMLs have been published
without these details, however more recently, when
chapters from a draft STG/EML are distributed for com-
ment, an accompanying document details the reasoning
and lists the evidence cited.
A comparative analysis of the WHO Model EML by
year since 1977 was conducted [10, 11] to describe the
process of development and updating of the list over time.
The importance of supporting evidence for the assessment
of safety, comparative effectiveness, and cost of medicines
was emphasized. The study showed an increase in the
overall number of molecules including duplicates (216 to
423) and the ratio between formulations/dosage forms
and molecules from 0 to 1.9 from the first edition in 1977
to 2009, indicating a similar trend to this study.
A study conducted in Croatia used the WHO Model
EML to assess the appropriateness of insurance coverage
decisions for the 2010 insurance coverage list compiled
by the Croatian Institute for Health Insurance (CIHI).
The study compared medicines on the CIHI Basic List
with the WHO EML and found 188 medicines in com-
mon. The WHO EML contained 32 individual and 10
combinations of the medicines which were absent on
the CIHI Basic List. Most differences were noted for in-
fectious diseases medicines [26]. This is fewer than the
SA STG/EMLs which had 101 individual and 11 combi-
nations of medicines that were absent but was similar
in that it also vastly differed in the anti-infectives medi-
cines category.
China has implemented an EML since 1982 and in
March 2013 released the new revised 2012 EML. China’s
EML contains both Western and Traditional Chinese
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medicines. Zang et al., (2003) analysed the new EML
and found an increase in total number of western mole-
cules (307 to 520) and number of formulations (780+ to
850+) from 2009 to 2012. China’s Ministry of Health also
hope to implement policies on restriction of medicine
utilization to EML items only for all government-based
PHC institutes; alignment of procurement policies for
EML items only; and make changes in the EML tender-
ing mechanisms [27]. China’s increasing trend in num-
ber of molecules and formulations is similar to the
increasing trend noted in SA STG/EMLs. Furthermore,
a comparison of China’s 2009 EML with WHO EML
showed that 132 medicines on the WHO EML were ab-
sent from China’s EML [28] which is almost similar to
the number of absent medicines on the SA STG/EMLs
in this study.
Tejani and Wertheimer (2014) analysed EMLs of ten
developing nations in Africa (excluding SA) and found
that most countries had on average 237 medications on
their EMLs compared to 350 on the 2013 WHO Model
EML. Eritrea had the most number of medications (354)
and Somalia the least (85). When compared to the
WHO EML, on average, most countries had 58.23% of
medicines in common, were lacking approximately 47%
of medicines, and had 30% additional medicines on their
EMLs. This comparison indicated that at least 18 medi-
cines were common among the countries (and not
present on the WHO EML) [29]. In comparison, our
study showed that SA had 112 absent medicines (exclud-
ing duplicates).
In 2012, Hill et al. performed a global survey of 89 coun-
try EMLs for inclusion of WHO PMWC (SA not in-
cluded). The most commonly listed medicines were as
follows: paracetamol (appeared on 94% of EMLs); Sodium
chloride, oral rehydration solution and gentamicin (93%).
Least commonly listed were children’s antimalarials (rectal
artesunate (8%); artesunate injection (16%); Paediatric ar-
temisinin combination therapy (36%); Procaine benzylpe-
nicillin (50%) and Zinc (15%). Analysis of medicines for
women showed the following: oxytocin (appeared on 62%
of EMLs); Magnesium sulphate (50%); misoprostol (35%);
and cefixime (26%). Our study showed similar results in
listing of common medicines for both mothers and chil-
dren and also did not list similar children’s medicines
since certain medicines (such as artesunate and artemisi-
nin combination therapy) as well as certain dosage forms
(such as dispersible, scored tablets for zinc, amoxicillin
and paracetamol) are not available in SA.
Limitations
This study did not consider SA’s Gross Domestic Prod-
uct, the budget for medicines, and the specific disease
burden for the country. It also did not examine the cri-
teria and processes for medicines selection for national
EMLs. This study also did not assess the impact on
health outcomes by implementation and changes in
SA STG/EMLs over time. These pose as limitations
in this study.
In addition, during the data analysis it was noted that
the index of drugs in the various SA STG/EMLs are not
complete, comprehensive listings of essential medicines.
Medicines that were mentioned in the STG were some-
times absent in the index of drugs. In addition, some
medicines were listed as their common names and
some were incorrectly spelt. This hinders the ability to
quickly find medicines and related treatment. Further-
more, a complete listing of registered drugs in SA is
not readily available.
Suggestions for future research
More research is required into the decision-making
process that the committees engage in during the review
process and on the impact of therapeutic class selection
in the procurement and use of medicines processes as
well as whether regular review processes impact on
STG/EML use and acceptance.
There is a dearth of published information on the
NEML changes (until just recently by the secretariat
within the National Department of Health), with regard to
the reasons for addition and deletion of medicines with
supporting evidence; processes and procedures of the
NEMLC regarding such changes and underlying policies
employed; and reports on implementation, monitoring
and evaluation of STG/EMLs in SA. Thus, these are rec-
ommendations for future research and for the workings of
the NEMLC to move towards a more transparent, fre-
quent reporting system as an approach to strengthen the
provision of health care in the country and also impacting
on improving access to pharmaceuticals and services from
a pharmaceutical policy point of view since NEMLC deci-
sions feed into the tendering and subsequent procurement
processes of pharmaceuticals.
SA has moved towards different levels of care. The EML
changes described in this study indicates the drive SA has
to define these various levels of care by introducing pre-
scriber levels, task shifting and the decentralization of
ARV services to PHC [19], and the production of a ter-
tiary/quaternary list, all of which aim to improve the
provision of healthcare in the public sector in SA.
What this study adds and implications for the SA process
Monitoring and evaluation of essential medicines pol-
icies, its implementation and outcomes is essential to
improve the efficiency and effectiveness of an EMP.
Regular assessment of the policy’s performance will pro-
vide insight into the costs, results and value of the
programme which ultimately informs the policy decision
making process and overall management of the policy
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and programme. The SA STG/EMLs have been imple-
mented for a few years now and there has been no ana-
lysis of this nature previously The analysis in this study
is the first of this kind and although it has revealed
changes, it is difficult to assess if these changes were ra-
tional nor are the underlying reasons for changes trans-
parent. Thus this study calls for continuous monitoring
of STG/EML changes.
Conclusions
This is the first study in SA to investigate changes in
NEMLs over time in relation to molecules, dosage forms
and therapeutic classes. It is also the first to compare
the latest SA EMLs to the WHO Model lists. The results
therefore provide insight into the SA EML processes
over time.
It is important to continue to monitor STG/EML de-
velopment and implementation, at both national and
provincial PTC levels, in order to understand the rea-
sons behind changes so as to adequately address the
healthcare needs of the population within budgetary
constraints of a country. The concept of essential medi-
cines has gained momentum worldwide, and evidence is
required to ascertain whether such a policy does make a
difference in outcomes for healthcare systems and pa-
tients. It is important to note that this study did not look
at decision making processes for EML selection in the
STG development process. From the changes that have
been described, there might have been some principles
employed in decisions. However, further studies are re-
quired to confirm this.
Endnotes
1This reference refers to the medicine procurement list
which is constantly updated and the most recent master
procurement list was reflected.
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